Risk increased for being admitted to the hospital or attending emergency care within 14 days with delta variant
Hospitalization rates among fully vaccinated higher among older residents of nursing homes and among those with underlying conditions
Lower hospitalization rates seen at 14, 21, 28 days for high-risk patients with mild-to-moderate COVID-19 who received casirivimab-imdevimab
Authors say that approximately one-tenth of patients with COVID-19 in U.K. hospitals were infected after admission
Vaccination coverages vary by state, with rates of one dose or more ranging from from 20.2 percent in Mississippi to 70.1 percent in Vermont
ACIP makes no preferential recommendation when more than one licensed, recommended vaccine is available
The Assistant Secretary for Preparedness and Response (ASPR) and the US Food and Drug Administration (FDA) announced on August 27, 2021, changes in the authorized use of monoclonal antibodies bamlanivimab and etesevimab administered together under Emergency Use Authorization (EUA) 094.
The ASPR will resume distribution of bamlanivimab and etesevimab together and etesevimab alone to pair with the existing supply of bamlanivimab at a facility for use under EUA.
Increase in demand for ivermectin has been accompanied by a fivefold increase in calls to poison control centers
COVID-19 deaths have also risen to an average of more than 1,000 a day for the first time since March
However, survivors had more problems with mobility, pain or discomfort, anxiety or depression at one year than controls